Imperva, Inc.
Imperva, Inc. Fundamental Analysis
Imperva, Inc. (IMPV) shows weak financial fundamentals with a PE ratio of 82.20, profit margin of 7.11%, and ROE of 8.36%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze IMPV's fundamental strength across five key dimensions:
Efficiency Score
WeakIMPV struggles to generate sufficient returns from assets.
Valuation Score
WeakIMPV trades at a premium to fair value.
Growth Score
WeakIMPV faces weak or negative growth trends.
Financial Health Score
ExcellentIMPV maintains a strong and stable balance sheet.
Profitability Score
WeakIMPV struggles to sustain strong margins.
Key Financial Metrics
Is IMPV Expensive or Cheap?
P/E Ratio
IMPV trades at 82.20 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, IMPV's PEG of 71.51 indicates potential overvaluation.
Price to Book
The market values Imperva, Inc. at 5.97 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -5.25 times EBITDA. This is generally considered low.
How Well Does IMPV Make Money?
Net Profit Margin
For every $100 in sales, Imperva, Inc. keeps $7.11 as profit after all expenses.
Operating Margin
Core operations generate -4.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.36 in profit for every $100 of shareholder equity.
ROA
Imperva, Inc. generates $4.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $1.58 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
82.20
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
71.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.97
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.71
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
-0.04
vs 25 benchmark
How IMPV Stacks Against Its Sector Peers
| Metric | IMPV Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 82.20 | 35.60 | Worse (Expensive) |
| ROE | 8.36% | 1040.00% | Weak |
| Net Margin | 7.11% | 5855262042.00% | Weak |
| Debt/Equity | 0.00 | 0.57 | Strong (Low Leverage) |
| Current Ratio | 2.71 | 5.05 | Strong Liquidity |
| ROA | 4.33% | -291580.00% (disorted) | Weak |
IMPV outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Imperva, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Growth, Innovation, High Beta
EPS CAGR
N/A
Industry Style: Growth, Innovation, High Beta
FCF CAGR
N/A
Industry Style: Growth, Innovation, High Beta